Europe CRISPR Gene Editing market was valued at $397.7 million in 2021 and will grow by 27.3% annually over 2021-2031, driven by the rising demand for better food and medical products, innovative advancement in gene therapy supported by the continued investments in healthcare, rising geriatric population and the increasing genomic and chronic diseases, and the development of rapid CRISPR-based POC tests amid COVID-19 pandemic.
Highlighted with 38 tables and 54 figures, this 125-page report Europe CRISPR Gene Editing Market 2021-2031 by Offering (Products, Services), Application (Biomedical, Agriculture, Industrial, Others), End User (Pharmaceutical Companies, Biotechnology Companies, Academic Institutions & Research Centers, Others), and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Europe CRISPR Gene Editing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
Market Structure
Growth Drivers
Restraints and Challenges
Emerging Product Trends & Market Opportunities
Porters Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe CRISPR Gene Editing market in every aspect of the classification from perspectives of Offering, Application, End User, and Country.

Based on Offering, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
CRISPR Products
o Kits & Enzymes
? Vector-Based Cas9
? DNA-Free Cas9
o Databases & Libraries
o Design Tools
o Antibodies
o CRISPR Plasmid & Vector
o Other Products
CRISPR Services
o gRNA Design & Vector Construction
o Cell Line Engineering
o Microbial Gene Editing
o DNA Synthesis
o Other Services

Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
Biomedical Research & Therapy
o Gene Therapy
o Drug Discovery
o Diagnostics
o Other Biomedical Applications
Agriculture
Industrial Use
Other Applications

By End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
Pharmaceutical Companies
Biotechnology Companies
Academic Institutions & Research Centers
Other End Users

Geographically, the following national/local markets are fully investigated:
Germany
UK
France
Spain
Italy
Netherlands
Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of key national markets by Offering, Application, and End User, over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abcam, Inc.
Agilent Technologies, Inc.
Applied StemCell, Inc.
Caribou Biosciences, Inc.
Cellecta, Inc.
CRISPR Therapeutics AG
Editas Medicine, Inc.
GeneCopoeia, Inc.
GeneScript Biotech Corporation
Horizon Discovery Group PLC
Integrated DNA Technologies, Inc.
Intellia Therapeutics Inc.
Lonza Group Ltd.
Merck KGaA
New England Biolabs, Inc.
Origene Technologies, Inc.
Rockland Immunochemicals, Inc.
Synthego Corporation
System Biosciences LLC
Takara Bio, Inc.
Thermo Fisher Scientific, Inc.
ToolGen, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)